ReAlta Life Sciences, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2018-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients with Steroid-Refractory Acute Graft-versus-Host Disease
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- ReAlta Life Sciences, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT06343792
- Locations
- 🇺🇸
Site 0191, Duarte, California, United States
🇺🇸Site 1343, Los Angeles, California, United States
🇺🇸Site 1318, Atlanta, Georgia, United States
Safety, PK and PD Relationships of RLS-0071 in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease
- Conditions
- Acute Exacerbation of Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-12-18
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- ReAlta Life Sciences, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT06175065
- Locations
- 🇺🇸
Site 02, Saint Petersburg, Florida, United States
🇺🇸Site 03, Glen Burnie, Maryland, United States
🇺🇸Site 04, Omaha, Nebraska, United States
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia
- First Posted Date
- 2023-03-21
- Last Posted Date
- 2025-07-25
- Lead Sponsor
- ReAlta Life Sciences, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT05778188
- Locations
- 🇺🇸
Study Site 016, Little Rock, Arkansas, United States
🇺🇸Study Site 013, Orange, California, United States
🇺🇸Study Site 020, San Diego, California, United States
A Clinical Study to Determine the Safety, Tolerability and Effect of RLS-0071 Doses When Given to Healthy Adults After Inhaling LPS
- Conditions
- Healthy
- Interventions
- Drug: RLS-0071 (10 mg/kg intravenously every 8 hours for total of 3 doses)Drug: RLS-0071 (loading dose of 120 mg/kg followed by 40 mg/kg every 8 hours for 2 additional doses)Drug: Placebo (saline dosed every 8 hours for a total of 3 doses)
- First Posted Date
- 2022-04-28
- Last Posted Date
- 2023-03-31
- Lead Sponsor
- ReAlta Life Sciences, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05351671
- Locations
- 🇩🇪
Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Hannover, Germany
A Phase 1 SAD/MAD Study of RLS-0071 in Healthy Volunteers in Support of a COVID-19 Development Program
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- ReAlta Life Sciences, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT05298787
- Locations
- 🇨🇦
Altasciences, Montreal, Quebec, Canada
- Prev
- 1
- 2
- Next